Cover Image
市場調查報告書

Zafgen Inc.:產品平台分析

Zafgen Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 255989
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Zafgen Inc.:產品平台分析 Zafgen Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 32 Pages
簡介

Zafgen Inc.是總公司設立於美國的生物製藥企業,正在開發肥胖及相關疾病的治療藥。致力於開發以脂肪組織為標的的藥劑,同時也提供減肥計劃、OTC藥、運動療法等。

本報告提供Zafgen Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Zafgen Inc. 的基本資料

  • Zafgen Inc. 概要
  • 主要資訊
  • 企業資料

Zafgen Inc. :R&D概要

  • 主要的治療範圍

Zafgen Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Zafgen Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Zafgen Inc. :藥物簡介

  • beloranib
  • Drugs to Inhibit Methionine Aminopeptidase 2 for Obesity
  • fumagillin
  • ZGN-839

Zafgen Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Zafgen Inc.:最近的開發平台形勢

Zafgen Inc.:開發暫停中的計劃

Zafgen Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07502CDB

Summary

Global Markets Direct's, 'Zafgen Inc. - Product Pipeline Review - 2015', provides an overview of the Zafgen Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zafgen Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zafgen Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zafgen Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zafgen Inc.'s pipeline products

Reasons to buy

  • Evaluate Zafgen Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zafgen Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zafgen Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zafgen Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zafgen Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zafgen Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zafgen Inc. Snapshot
    • Zafgen Inc. Overview
    • Key Information
    • Key Facts
  • Zafgen Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Zafgen Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Zafgen Inc. - Pipeline Products Glance
    • Zafgen Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Zafgen Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Zafgen Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Zafgen Inc. - Drug Profiles
    • beloranib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Methionine Aminopeptidase 2 for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fumagillin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZGN-839
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zafgen Inc. - Pipeline Analysis
    • Zafgen Inc. - Pipeline Products by Target
    • Zafgen Inc. - Pipeline Products by Route of Administration
    • Zafgen Inc. - Pipeline Products by Molecule Type
    • Zafgen Inc. - Pipeline Products by Mechanism of Action
  • Zafgen Inc. - Recent Pipeline Updates
  • Zafgen Inc. - Dormant Projects
  • Zafgen Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zafgen Inc., Key Information
  • Zafgen Inc., Key Facts
  • Zafgen Inc. - Pipeline by Indication, 2015
  • Zafgen Inc. - Pipeline by Stage of Development, 2015
  • Zafgen Inc. - Monotherapy Products in Pipeline, 2015
  • Zafgen Inc. - Partnered Products in Pipeline, 2015
  • Zafgen Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Zafgen Inc. - Phase III, 2015
  • Zafgen Inc. - Phase II, 2015
  • Zafgen Inc. - Preclinical, 2015
  • Zafgen Inc. - Pipeline by Target, 2015
  • Zafgen Inc. - Pipeline by Route of Administration, 2015
  • Zafgen Inc. - Pipeline by Molecule Type, 2015
  • Zafgen Inc. - Pipeline Products by Mechanism of Action, 2015
  • Zafgen Inc. - Recent Pipeline Updates, 2015
  • Zafgen Inc. - Dormant Developmental Projects,2015

List of Figures

  • Zafgen Inc. - Pipeline by Top 10 Indication, 2015
  • Zafgen Inc. - Pipeline by Stage of Development, 2015
  • Zafgen Inc. - Monotherapy Products in Pipeline, 2015
  • Zafgen Inc. - Partnered Products in Pipeline, 2015
  • Zafgen Inc. - Pipeline by Top 10 Target, 2015
  • Zafgen Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Zafgen Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Zafgen Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top